Foley Hoag Advises Trio of Investors in Series A Financing of Editas Medicine

Foley Hoag LLP recently represented Flagship Ventures, Polaris Partners and Third Rock Ventures in their $43 million Series A investment in genome editing startup Editas Medicine.

Based in Cambridge, Mass., Editas Medicine aims to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. Polaris Partners principal Kevin Bitterman will act as Editas interim president and Third Rock Ventures partner Lou Tartaglia, Ph.D. will act as interim chief scientific officer. The Editas board of directors will include Flagship Ventures general partner Douglas Cole, M.D. and Polaris Partners co-founder and general partner Terry McGuire.

A Foley Hoag team consisting of Robert Birnbaum, Matthew Eckert and Patrick Connolly advised the three investors, who were also joined by Partners Innovation Fund in the investment.

About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™, which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000 and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. For more information, please visit

About Polaris Partners
Founded in 1996, Polaris Partners has more than $3.5 billion in capital under management which we invest into a diverse portfolio of technology and healthcare companies throughout their lifecycles. From the earliest startup phases through the growth equity stages, Polaris Partners takes minority and majority positions alongside outstanding management teams to help grow industry leading companies like Ascend, Avila, Ironwood, Receptos, LogMeIn and Akamai. With offices in Boston, San Francisco and Dublin, Polaris partners with an unparalleled network of repeat CEOs, entrepreneurs, top scientists and emerging innovators who are positioned to make a significant impact in their fields and vastly improve the way in which we all live and work. For more information, visit

About Third Rock Ventures
Third Rock Ventures is a leading healthcare venture firm focused on investing and launching companies that make a difference in people’s lives. The Third Rock team has a unique vision for ideating and building transformative healthcare companies. Working closely with our strategic partners and entrepreneurs, Third Rock has an extensive track record for managing the value creation path to deliver exceptional performance. For more information, please visit the firm’s website at